JPMorgan raised the firm’s price target on Stoke Therapeutics (STOK) to $25 from $15 and keeps a Neutral rating on the shares ahead of the Q3 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- STOK Earnings this Week: How Will it Perform?
- Stoke Therapeutics Advances Phase 3 Study for Dravet Syndrome Treatment
- Stoke Therapeutics presents two-year data from FALCON study
- Promising Potential of Stoke Therapeutics’ Zorevunersen as a Disease-Modifying Therapy for Dravet Syndrome: Analyst Recommends Buy Rating
- Stoke Therapeutics price target raised to $35 from $22 at Needham